Abivax S.A.
ABVX
Classificação em ações
#2353
Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013,... Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013, dedicated to identifying and refining treatments for various serious conditions, including inflammatory and infectious diseases, as well as cancer. Its primary drug candidate, ABX464, is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's disease, and COVID-19, and is in Phase IIa trials for rheumatoid arthritis. This compound has also successfully completed a Phase IIa study focused on achieving viral remission in HIV patients. Additionally, the company is advancing ABX 196, an immune-enhancing agent, through Phase 1/2 clinical trials for hepatocellular cancer. Beyond these main programs, Abivax is also engaged in research initiatives targeting Dengue fever, influenza, and the respiratory syncytial virus. The company holds significant licensing agreements with esteemed institutions such as the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie.
Preço da ação
$95.29
Última sincronização: 2026-10-21
Valor de mercado
$8.32B
Variação (1 dia)
-3.50%
Variação (1 ano)
7.83%
País
FR
Negociar Abivax S.A. (ABVX)
Categoria
Healthcare
Rácio P/S de Abivax S.A. (ABVX)
Rácio P/S em 2026 TTM: 0
De acordo com os relatórios financeiros mais recentes e o preço das ações da Abivax S.A., o rácio P/S atual (TTM) é 0. No final de 2026, o rácio P/S era 0.
Histórico do rácio P/S da Abivax S.A. de 2026 a 2026
Rácio P/S no final de cada ano
| Ano | Rácio P/S | Alterar |
|---|---|---|
| Não há dados suficientes para as datas fornecidas. | ||
Rácio P/S de empresas semelhantes ou concorrentes
| Empresa | Rácio P/S | Diferença do rácio P/S | País |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| 10.15 | - |
NL
|
|
| - | - |
CH
|
